MADD: First Causal Gene for Quantitative Von Willebrand Disease Discovered
Isabel Bär, PhD candidate at Erasmus MC, shared a proud post on LinkedIn:
”Unraveling the cause of a rare disease by studying an even rarer disease… Who says scientists aren’t creative!
So proud of my amazing colleague Sophie Hordijk, under supervision of Ruben Bierings and Frank Leebeek, for investigating the secretion machinery in a disease affecting only 26 patients worldwide and uncovering insights that bring us closer to solving a major mystery in the most common inherited bleeding disorder globally: Von Willebrand disease.
These findings could help explain why around 20% of Von Willebrand disease patients bleed without carrying mutations in their Von Willebrand factor gene. The identification of MADD as the first causal gene for quantitative Von Willebrand disease is a great example of how rare disease research can unlock answers to broader medical questions.
No wonder that Amazing Erasmus MC picked up on it – truly amazing work, congratulations!
If you want to know why it was necessary to go to 4 different countries (Czech Republic, Germany, Belgium, and the UK) to perform this study, check out the interview.
And if you’re looking for a deeper scientific dive beyond this interview, check the recently published results in Blood!”
To learn more, follow the link.
Read the full article here.
Article: A novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variants
Authors: Sophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N.J. Laan, Georg-Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W.G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben Bierings
Stay updated on the latest scientific advancements in the field of bleeding disorders with Hemostasis Today.
-
Nov 4, 2025, 09:26Courtney Lawrence: One of Our Most Popular American Red Cross SUCCESS Talks is Just Around the Corner!
-
Nov 4, 2025, 09:21New Study by Emmanuel J Favaloro and Team Questions Consistency in APS Classification and Diagnosis
-
Nov 4, 2025, 09:20Yazan Abou Ismail to Present Insights on AI Models in TTP at 67th ASH Annual Meeting
-
Nov 4, 2025, 09:17David Calvet Canut on Takeda's HyHub: A Shift Toward Patient-Centered Biologics
-
Nov 4, 2025, 09:16Samantha Nelson Encourages You to Share Your Experience on World Thrombosis Day
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!